PDF
Kurs & Likviditet
Beskrivning
| Land | Danmark |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES.
Hørsholm, Denmark, 13 April 2022 - The Board of Directors of ExpreS2ion Biotech Holding AB (publ) ("ExpreS2ion" or the "Company") announced on 6 April 2022, on the basis of the authorization from the Annual General Meeting on 26 May 2021, to resolve to carry out a fully guaranteed new share issue with preferential rights for the Company's existing shareholders (the "Rights Issue"). The Company will upon full subscription of the Rights Issue receive gross proceeds of approximately SEK 73 million. The Board of Directors of ExpreS2ion has in connection with the Rights Issue, and prior to the subscription period, which commences on 19 April 2022, prepared a prospectus which today has been approved by the Swedish Financial Supervisory Authority (Sw. Finansinspektionen) (the "SFSA"). The prospectus has been published on the Company's website and is available in Swedish and English.
Publication of the prospectus
For complete information about the Rights Issue, please refer to the prospectus that has been prepared by the Company and that today has been approved by the SFSA. The prospectus is available in Swedish and English on ExpreS[2]ion's website (https://investor.expres2ionbio.com/) and will also be available on the SFSA's website (https://fi.se/sv/vara-register/prospektregistret/). The prospectus will be passported to Denmark and thus also available for Danish investors.
The prospectus is prepared as an EU-Growth prospectus in accordance with article 15 in the Regulation (EU) 2017/1129 (the "Prospectus Regulation"). The prospectus has been approved by the SFSA, which is the Swedish competent authority in accordance with the Prospectus Regulation, in accordance with article 20 in the Prospectus Regulation. The SFSA only approves the prospectus as meeting the standards of completeness, comprehensibility and consistency imposed by the Prospectus Regulation. The approval should not be considered as an endorsement of ExpreS[2]ion or as an endorsement of the quality of the shares that are the subject of the prospectus and does not indicate that the SFSA guarantees that the facts in the prospectus are correct or complete. Investors should make their own assessment as to the suitability of investing in the Rights Issue.
The Rights Issue in briefThe maximum number of shares that may be issued is 5,841,273. The subscription price is SEK 12.50 per share. The Company will receive proceeds of approximately SEK 73 million before deduction of costs attributable to the Rights Issue, which is expected to amount to approximately SEK 12.3 million.
The subscription price of SEK 12.50 per share corresponds to a discount of approximately 31 percent compared to the 10 days volume-weighted average price ("VWAP") on Nasdaq First North Growth Market Stockholm.
Those who are registered as shareholders in ExpreS[2]ion's share register on the record date receive three (3) subscription rights for every eight (8) shares held in ExpreS[2]ion. Where two (2) subscription rights entitle to subscription for one (1) new share.
Record date for participation in the Rights Issue is 13 April 2022.
Subscription period of the Rights Issue runs from 19 April up until 3 May 2022.
The Rights Issue is fully guaranteed through subscription commitments of approximately SEK 1.8 million, corresponding to approximately 2.5 percent of the Rights Issue, and guarantee undertakings of approximately SEK 71.2 million, corresponding to approximately 97.5 percent of the Rights Issue. Members of the Board of Directors and the senior management have committed to subscribe for new shares.
The expected net proceeds from the Rights Issue will be used as to (i) advance the breast cancer vaccine candidate ES2B-C001 to completion of the preclinical safety studies (approximately 50 percent), (ii) advance other pipeline development projects, including within Influenza and Malaria, and support the strategic CRO business (approximately 25 percent), (iii) and invest in core technologies and IP to strengthen competitive edge (approximately 25 percent).
Complete terms and conditions of the Rights Issue are disclosed in the prospectus.
Timetable for the Rights Issue
Subscription period 19 April - 3 May 2022
Trading in Subscription 19 April - 28 April 2022
rights
Trading in BTAs (Paid 19 April 2022 until the Rights Issue is registered
subscribed New shares) with Swedish Companies Registration Office (Sw.
Bolagsverket)
Announcement of final On or around 5 May 2022
outcome in the Rights
Issue
Advisors
Vator Securities act as financial advisor and issuing agent to the Company in connection with the Rights Issue. Baker Mckenzie is the Company's legal advisor in connection with the Rights Issue.
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
Telefon: +46 11 32 30 732
E-post: ca@skmg.se